Gene · 53353
Papers2,235
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 2,235
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrated analysis of single-cell and Bulk RNA sequencing reveals a malignancy-related signature in lung adenocarcinoma. | Front Oncol | 2023 | 37427142 | PubTator, text mining | PubMed |
| Genomic profiles of renal cell carcinoma in a small Chinese cohort. | Front Oncol | 2023 | 37427096 | PubTator, text mining | PubMed |
| Functionalized nanoparticles crossing the brain-blood barrier to target glioma cells. | PeerJ | 2023 | 37426416 | PubTator, text mining | PubMed |
| RNF43 is associated with genomic features and clinical outcome in BRAF mutant colorectal cancer. | Front Oncol | 2023 | 37409251 | PubTator, text mining | PubMed |
| Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas. | Biomark Res | 2023 | 37403120 | PubTator, text mining | PubMed |
| PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma. | Front Immunol | 2023 | 37398672 | PubTator, text mining | PubMed |
| Hallmark guided identification and characterization of a novel immune-relevant signature for prognostication of recurrence in stage I-III lung adenocarcinoma. | Genes Dis | 2023 | 37397559 | PubTator, text mining | PubMed |
| Development and validation of cancer-associated fibroblasts-related gene landscape in prognosis and immune microenvironment of bladder cancer. | Front Oncol | 2023 | 37397364 | PubTator, text mining | PubMed |
| Comprehensive Mutation Profiling of Colorectal Cancer Patients With Lung or Liver Metastasis by Targeted Next-Generation Sequencing. | Technol Cancer Res Treat | 2023 | 37394872 | PubTator, text mining | PubMed |
| Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial. | ESMO Open | 2023 | 37379764 | PubTator, text mining | PubMed |
| Glutamine metabolism genes prognostic signature for stomach adenocarcinoma and immune infiltration: potential biomarkers for predicting overall survival. | Front Oncol | 2023 | 37377916 | PubTator, text mining | PubMed |
| Whole-genome and Epigenomic Landscapes of Malignant Gastrointestinal Stromal Tumors Harboring KIT Exon 11 557-558 Deletion Mutations. | Cancer Res Commun | 2023 | 37377752 | PubTator, text mining | PubMed |
| Identification of Somatic Mutations in Plasma Cell-Free DNA from Patients with Metastatic Oral Squamous Cell Carcinoma. | Int J Mol Sci | 2023 | 37373553 | PubTator, text mining | PubMed |
| A Pan-Cancer Analysis of Prognostic and Immunological Roles for Cell Death Genes. | Genes (Basel) | 2023 | 37372358 | PubTator, text mining | PubMed |
| Identifying Cancer Driver Pathways Based on the Mouth Brooding Fish Algorithm. | Entropy (Basel) | 2023 | 37372185 | PubTator, text mining | PubMed |
| Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma. | Biomolecules | 2023 | 37371463 | PubTator, text mining | PubMed |
| The Distinctive Features behind the Aggressiveness of Oral and Cutaneous Squamous Cell Carcinomas. | Cancers (Basel) | 2023 | 37370836 | PubTator, text mining | PubMed |
| Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer. | Cancers (Basel) | 2023 | 37370686 | PubTator, text mining | PubMed |
| Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. | Curr Oncol | 2023 | 37366888 | PubTator, text mining | PubMed |
| Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer. | Mol Oncol | 2023 | 37356061 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/53353/papers?page=18